ARA-290
An overview of erythropoietin-derived peptide research without turning orphan-drug development into a wellness claim.
At a glance
- Evidence stage
- Early human
- Regulatory status
- Investigational peptide studied in early human trials for nerve and inflammatory conditions; not FDA-approved.
- Research context
- ARA-290 (cibinetide) is an erythropoietin-derived peptide researched for nerve-fiber and inflammatory outcomes in early human studies; findings remain preliminary.
What this is
- ARA-290 has moved into early human clinical study for specific research questions.
- Results so far are preliminary and limited to the populations and endpoints studied.
- ARA-290 is not yet FDA-approved for any indication.
What this isn't
- This page is not medical advice or a treatment recommendation involving ARA-290.
- This is not confirmation that ARA-290 is approved, safe, or ready for general use.
- This is not a dosing guide.
Key terms
Educational information only — not medical advice. This page does not diagnose conditions, recommend treatment, or replace care from a qualified clinician. The Peptide Center uses an evidence-first editorial process: regulatory sources, trial registries, and peer-reviewed research take priority; uncertainty is stated rather than filled with promises.
ARA-290, also known as cibinetide, is an erythropoietin-derived peptide studied in neuropathy and tissue-protection research, including orphan-drug development pathways. Investigational status and specialized trial populations mean results may not apply to general recovery or performance marketing.
Evidence limits
How to read the evidence
Educational information only — not medical advice. This page does not diagnose conditions, recommend treatment, or replace care from a qualified clinician. The Peptide Center uses an evidence-first editorial process: regulatory sources, trial registries, and peer-reviewed research take priority; uncertainty is stated rather than filled with promises.
Orphan-designation and trial activity indicate research interest, not universal availability or proven benefit for off-label uses. Read the indication, route (often investigational IV in trials), and endpoints carefully.
Coverage
In the news
Recent reporting about this molecule. Headlines are not clinical guidance.
- Araim Pharmaceuticals' Cibinetide (ARA 290) Regenerates Small Nerve Fibers and Improves Neuropathic Clinical Symptoms in the Orphan Disease of Sarcoidosis - PR NewswirePR Newswire · 2017-05-08 · External ↗
- Exploring the Multifaceted Potential of ARA-290 Peptide in Diverse Research Domains - Nagpur TodayNagpur Today · 2025-08-07 · External ↗
- ARA-290: Reframing a Tissue-Protective Peptide Within Emerging Cellular Signaling Landscapes - Henry HeraldHenry Herald · 2026-07-24 · External ↗
External sources and citations
- ARA290 Attenuates Apical Periodontitis via SIRT1/NF-κB/IL-1β Pathway Modulation. International dental journal, 2025
- Nonerythropoietic Erythropoietin Mimetic Peptide ARA290 Ameliorates Chronic Stress-Induced Depression-Like Behavior and Inflammation in Mice. Frontiers in pharmacology, 2022
- Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the β-common receptor in mice with cerebral ischemic stroke. CNS neuroscience & therapeutics, 2024
- A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. Journal of clinical medicine, 2020
- Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways. Inflammation, 2023
- Renoprotective capacities of non-erythropoietic EPO derivative, ARA290, following renal ischemia/reperfusion injury. Journal of translational medicine, 2013
Common questions
What is ARA-290?
ARA-290 is discussed in research and educational contexts as a named molecule or product label. Identity, purity, and studied form can differ across sources — a name match alone is not proof of the same material used in a study.
What does the evidence for ARA-290 actually show?
Evidence for ARA-290 ranges by question: preclinical models, early human work, or approved uses for specific indications. Mechanism findings and animal data do not automatically predict clinical benefit or safety in people.
Is ARA-290 FDA-approved for general use?
Do not assume ARA-290 is FDA-approved for the use you have in mind. Approvals are indication-specific. Many research peptides and compounded products are not approved drugs for consumer or athletic use.
What product-quality questions should I ask about ARA-290?
Ask what was tested (identity, purity, potency), who tested it, and whether the label matches the studied form. Third-party certificates, storage conditions, and supplier transparency matter more than marketing claims.
How is ARA-290 different from similarly named products?
Blends, salts, fragments, and brand nicknames are often confused with ARA-290. Verify the exact molecule, dose unit, and route in any citation before treating it as evidence for a different product.
Related peptides
Other published briefs in the same research family. Educational references only - not treatment recommendations.
B7-33
B7-33 is a scientifically interesting relaxin mimetic, but its evidence remains preclinical.
Open resourcePeptide briefBPC-157
A conservative review of what laboratory findings can and cannot tell us about BPC-157.
Open resourcePeptide briefCardiogen
Why the same acronym can refer to different molecules, salts, fragments, or blends.
Open resourcePeptide briefCartalax
Why a compelling cell or animal result is the beginning of a question, not the end of it.
Open resourcePeptide briefCurcumin
Why the same acronym can refer to different molecules, salts, fragments, or blends.
Open resourceArticles about this peptide
Curated editorial articles that directly reference this peptide. These are educational resources, not treatment recommendations.
Learn the research basics
Foundational literacy pieces that help interpret evidence stage, product identity, and study design.
How to read a peptide study without overclaiming
A practical guide to research stage, controls, endpoints, uncertainty, and applicability.
Open resourceLiteracyWhy a biological mechanism is not a treatment promise
A practical explanation of why plausible pathways still need meaningful human-outcome evidence.
Open resourceLiteracyPeptide naming, aliases, and product identity
Why the same acronym can refer to different molecules, salts, fragments, or blends.
Open resourceLiteracyFrom preclinical finding to human evidence
Why a compelling cell or animal result is the beginning of a question, not the end of it.
Open resourceLiteracyFDA approved, compounded, and unapproved are not synonyms
A plain-language map of product categories that are often blurred in peptide discussions.
Open resourceLiteracyUnderstanding surrogate endpoints in peptide research
When a laboratory value changes but patient outcomes remain uncertain.
Open resourceWatch & read
Same-family videos and articles from the Articles & Media channel. Educational references only.
KLOW - Dr Explains The Peptide Stack For Healing, Inflammation and Regeneration
In this video, I break down the research on foundational healing and regeneration peptide stacks — BPC-157, TB-500, GHK-Cu, and KPV. These four peptides work on different layers of repair — from gut and tissue healing to inflammation control and skin remodeling — and when combined strategically, they could create a powerful synergy for recovery, longevity, and performance. You’ll learn: 🔥 How BPC-157 and TB-500 accelerate tissue and tendon repair 🧬 How GHK-Cu supports collagen, skin tone, and cellular regeneration 💊 Why KPV calms inflammation and protects the gut-skin axis 🧩 How to safely combine and cycle these peptides for optimal results This isn’t medical advice — it’s education for people who want to understand how the body actually heals itself when you support it the right way. Always consult your licensed provider before using or compounding peptides. Master Peptides https://courses.drafroese.com/ Affiliate Links (I do make a small commission if you purchase through these links): Oral BPC157 supplements: https://bit.ly/45DOjXF The Cold Plunge I personally use: https://titan-wellness.com/?ref=ASHLEYFROESE
Open resourceVideoWHAT IS THE BEST PEPTIDE TO HELP HEALING FROM AN INJURY? | ASK THE DOC.
On this new episode of Ask the Doc, a viewer asks, between ALL the available peptides today, what is the BEST one to help healing from an injury and what the the appropriate dosage? Enjoy! SUPPLEMENTS (20% OFF): https://jaycutler.com/discount/JAYTV20?aff=JAYTV20 TRT KINGDOM: https://trtkingdom.com/?ref=Jay-Cutler EXCLUSIVE CONTENT: https://www.facebook.com/JayCutler4x SNAPCHAT for BTS content: https://www.snapchat.com/add/mrojaycutler MEGAFIT MEALS - : https://megafitmeals.com Code: JAY FAT GRIPZ: https://amzn.to/3A3PHG4 JOIN CUTLER CLUB: https://cutlerclub.com MEMORABILIA/POSTERS / SIGNED ITEMS: https://www.jaycutlershop.com Code: CUTLER FREE NEWSLETTER: https://jaymail.jaycutler.club PODCAST: https://www.youtube.com/c/CutlerCast JAY'S PET BUTTER: https://jayspetbutter.com #JayCutler #BackDay #Bodybuilding
Open resourceVideoThe 4 Most Impactful Peptides for my Chronic Pain
0:00 Introduction 0:34 What is Peptide Therapy 1:23 Growth Hormone Secretagogues 2:46 BPC-157 3:29 TB500 4:20 GHK-Cu 5:01 Dosing Peptides are gaining popularity for their role in managing chronic pain, and in this video, we'll explore the four peptides I personally use: growth hormone secretagogues, BPC 157, TB500, and GHK Copper. These peptides help reduce inflammation, stimulate tissue repair, and promote collagen production, offering a broad safety profile compared to pharmaceuticals. I'll also discuss the most common dosing strategies we use to maximize their effectiveness in treating pain. Remember, always consult with your doctor before starting any peptide therapy. Want to OVERCOME chronic pain? Go here: https://regenerativeperformance.com/dr-drew-timmermans If you’re new to my channel, my name is Dr. Drew Timmermans, ND, RMSK. I’m the founder of Regenerative Performance in Gilbert, AZ, specializing in interventional orthobiologics, which is just a fancy way of saying we help people reclaim their life from chronic pain without steroids or surgery. We challenge the conventional pain management approaches by addressing the root causes of chronic pain. How I got here… 22 yrs old: Graduated with a Bachelor of Science in Kinesiology from the University of Western Ontario. 23 yrs old: Competed as a long sprinter, anchoring the 4x400m relay to a silver medal at the Canadian national championships, contributing to Western's first national title in men's track and field. 23 yrs old: Started working as a personal trainer for GoodLife Fitness in Canada, quickly becoming one of the Top 10 Personal Trainers nationwide. 23 yrs old: Herniated two discs in my lower back, ending my track and field career and sending me into a multi-year battle with chronic pain. 24 yrs old: Enrolled at the Southwest College of Naturopathic Medicine (now Sonoran University of Health Sciences) after discovering my passion for naturopathic medicine. 26 yrs old: Still battling chron
Open resourceVideoPeptides for Muscle Recovery & Injury Healing
Injury recovery can be frustrating, especially when progress slows or stalls. In this video, Grant Pagdin explains how certain peptides are being explored to support tissue repair and muscle recovery. He discusses the two main recovery pathways peptides may support: direct connective tissue repair and growth hormone stimulation. The conversation also highlights why peptides work best when combined with physiotherapy, nutrition, and proper rehab. Important considerations around athletic competition and anti-doping regulations are covered as well. This video offers a balanced look at where peptides may fit into a responsible recovery strategy.
Open resourceArticleKPV: anti-inflammatory tripeptide research
How to read KPV gut-skin and inflammation literature without overstating preclinical findings.
Open resourceArticleMelanotan II: regulatory warnings and risk context
FDA consumer warnings, unapproved status, and why tanning or libido claims are not benign.
Open resourceRelated articles
Same-family articles from the published library. Educational references only - not treatment recommendations.
KPV: anti-inflammatory tripeptide research
How to read KPV gut-skin and inflammation literature without overstating preclinical findings.
Open resourceArticleARA-290 (cibinetide): neuropathy and repair research
An overview of erythropoietin-derived peptide research without turning orphan-drug development into a wellness claim.
Open resourceArticleMelanotan II: regulatory warnings and risk context
FDA consumer warnings, unapproved status, and why tanning or libido claims are not benign.
Open resource